Telix Pharmaceuticals Overview

  • Founded
  • 2015
Founded
  • Status
  • Public
  • Stock Symbol
  • TLX
Stock Symbol
  • Investments
  • 5
  • Share Price
  • $3.88
  • (As of Tuesday Closing)

Telix Pharmaceuticals General Information

Description

Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer. Geographically, it operates in Australia, the United States, Belgium, and Japan.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
ASX
Primary Office
  • 55 Flemington Road
  • Suite 401
  • North Melbourne, Victoria 3051
  • Australia

Telix Pharmaceuticals Timeline

2018201920202021
Financing Round
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Telix Pharmaceuticals Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.88 $3.87 $0.89 - $5.04 $1.09B 282M 781K

Telix Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 30-Jun-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 1,229,233 756,706 245,110 83,046
Revenue 3,219 2,422 146
EBITDA (28,850) (17,081) (11,952)
Net Income (30,873) (19,368) (10,324)
Total Assets 121,342 71,834 54,033
Total Debt 1,697 1,492 1,218
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Telix Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Telix Pharmaceuticals‘s full profile, request access.

Request a free trial

Telix Pharmaceuticals Executive Team (10)

Name Title Board Seat Contact Info
Christian Behrenbruch Ph.D Co-Founder, Chief Executive Officer & Board Member
Douglas Cubbin Chief Financial Officer
Gabriel Liberatore Chief Operating Officer
Melanie Farris Chief Governance and Risk Officer, Group Company Secretary
Jyoti Arora Ph.D Director of Operations
You’re viewing 5 of 10 executive team members. Get the full list »

Telix Pharmaceuticals Board Members (5)

Name Representing Role Since
Christian Behrenbruch Ph.D Telix Pharmaceuticals Co-Founder, Chief Executive Officer & Board Member 000 0000
You’re viewing 1 of 5 board members. Get the full list »

Telix Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Telix Pharmaceuticals‘s full profile, request access.

Request a free trial

Telix Pharmaceuticals Investments & Acquisitions (5)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000000 14-Dec-2020 000000000000000000 000.00 Biotechnology 000000000 00000000000 00.0
0000 24-Dec-2018 000000000000000000 00.000 Distributors (Healthcare) 000000000 00000000000 00.0
00000 000000 11-Sep-2018 000000000000000000 0000 Therapeutic Devices 000000000 00000000000 00.0
00000 0000000 24-Oct-2017 00000 0000000 Diagnostic Equipment
Therapeia 18-Jan-2017 Merger/Acquisition Drug Discovery 000000000 00000000000 00.0
To view Telix Pharmaceuticals’s complete investments and acquisitions history, request access »

Telix Pharmaceuticals Subsidiaries (3)

Company Name Industry Location Founded
ANMI Distributors (Healthcare) Liège, Belgium 2015
0000000000 Biotechnology Zákolany, Czech Republic 0000
000000000 Drug Discovery Dresden, Germany 0000
To view Telix Pharmaceuticals’s complete subsidiaries history, request access »